Eli Lilly & Co. kicked off 2025 in style, unveiling impressive results in its quarterly report that confirm its position as one of the fastest-growing players in the pharmaceutical industry. The main credit for this goes to Mounjaro and Zepbound, which saw a significant increase in sales, which reflected positively on the company's overall sales and profits. This growth has been accompanied by significant investment in research, development and expansion of production capacity to further strengthen the company's competitive advantage in the global market.

In addition to the impressive financial results, the company continues to innovate and develop new medicines that promise to improve healthcare in key areas such as diabetes, obesity and oncology. Eli Lilly also reaffirms its optimistic full-year outlook and declares ambitious expansion plans, which include building new manufacturing facilities and strategic partnerships with other companies.

How was the last quarter?

In its quarterly…